Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | PTGER4 | P35408 | 7/20 | 0.44 |
| ▸ | PTGER2 | P43116 | 7/20 | 0.44 |
| ▸ | PTGER3 | P43115 | 7/20 | 0.44 |
| ▸ | PTGER1 | P34995 | 5/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 4/20 | 0.42 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.40 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.39 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.39 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.39 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5110036 | 1.00 | KDM4E (0.46) | KDM4EALDH1A1PKMLMNAPTGER4 | |
| SCHEMBL6035428 | 0.84 | PKM (0.52) | KDM4EALDH1A1PKMLMNAPTGER4 | |
| SCHEMBL6035432 | 0.84 | PKM (0.52) | KDM4EALDH1A1PKMLMNAPTGER4 | |
| SCHEMBL5106916 | 0.84 | KDM4E (0.44) | KDM4EALDH1A1PKMLMNAPTGER4 | |
| SCHEMBL5106913 | 0.84 | KDM4E (0.44) | KDM4EALDH1A1PKMLMNAPTGER4 | |
| SCHEMBL5114932 | 0.84 | PKM (0.45) | ALDH1A1PKMLMNA | |
| SCHEMBL5107853 | 0.82 | KDM4E (0.48) | KDM4EALDH1A1PKMLMNAPTGER4 | |
| SCHEMBL5107858 | 0.82 | KDM4E (0.48) | KDM4EALDH1A1PKMLMNAPTGER4 | |
| SCHEMBL5405458 | 0.81 | ALDH1A1 (0.48) | KDM4EALDH1A1PKMLMNAPTGER4 | |
| SCHEMBL5405463 | 0.81 | ALDH1A1 (0.48) | KDM4EALDH1A1PKMLMNAPTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051418-A1 | Arylalkanoic Acid Derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-02-28 | — | — | US | disclosed |
| EP-1829863-A1 | ARYLALKANOIC ACID DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2007-09-05 | — | — | EP | disclosed |
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | GPR119, SLC5A1, CYP4B1 | KDM4E 509/4885ALDH1A1 1442/4885PKM 2082/4885 |
| US-20080051418-A1 | Arylalkanoic Acid Derivative | INSR, NPY1R, GPR119 | KDM4E 1854/4885ALDH1A1 1527/4885PKM 3398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.